New drug combo aims to keep advanced lung cancer in check

NCT ID NCT07110103

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help people with extensive-stage small cell lung cancer (SCLC) stay progression-free longer. Twenty adults who have not yet been treated for their advanced SCLC will receive the drug combination after initial chemotherapy. The study is open-label and single-arm, meaning everyone gets the experimental treatment, and it is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: golidocitinib (AZD4205) combined with PD-1 inhibitors
What this could lead to: If successful, this could offer a new maintenance treatment option to help control extensive-stage small cell lung cancer and potentially extend the time before the disease worsens.
What could go wrong: This is a small, early-phase (Phase 2) study with only 20 participants, so results may not apply broadly. The combination therapy may cause side effects or fail to improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC SCLC, EXTENSIVE STAGE

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China
Xinqiao Hospital, Third Military Medical University
RECRUITING

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.